STOCK TITAN
  1. Home
  2. News
  3. INO

INOVIO to Present at Jefferies 2022 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PLYMOUTH MEETING, Pa., May 23, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, and Jeffrey Skolnik, M.D., SVP of Clinical Development for Oncology and HPV Therapeutics, are scheduled to participate in a fireside chat and 1x1 investor meetings at the Jefferies 2022 Healthcare Conference on Wednesday, June 8th, 2022 at 1:00 PM EDT.

Jefferies 2022 Healthcare Conference
Date: Wednesday, June 8, 2022
Time: 1:00 PM EDT
Presentation Format: Fireside Chat

A webcast of the presentation will be available through the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. The presentation time is subject to change.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. Our DNA medicines are delivered using our proprietary smart device to produce a robust and tolerable immune response against targeted pathogens and cancers.

Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit www.inovio.com.

CONTACTS:

Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com

 

Cision View original content:https://www.prnewswire.com/news-releases/inovio-to-present-at-jefferies-2022-healthcare-conference-301552645.html

SOURCE INOVIO Pharmaceuticals, Inc.

Stock INO logo
Inovio Pharmaceuticals, Inc.

NASDAQ:INO

INO Rankings

#3480 Ranked by Market Cap
#5361 Ranked by Stock Gains
N/A Ranked by Dividends

INO Latest News

May 1, 2024
INOVIO Reports Inducement Grants Under Inducement Plan
Apr 29, 2024
INOVIO to Participate in Upcoming Investor Conferences in May
Apr 29, 2024
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
Apr 15, 2024
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Mar 26, 2024
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

INO Stock Data

288.86M
22.99M
1.61%
17.98%
9%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About INO

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.